非在研机构- |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)临床3期 |
特殊审评孤儿药 (欧盟) |
分子式C36H40FN9O3 |
InChIKeyLCFFREMLXLZNHE-GBOLQPHISA-N |
CAS号1575596-29-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11873 | - | - | - |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
天疱疮 | 临床1期 | 澳大利亚 | 2019-01-08 | |
天疱疮 | 临床1期 | 克罗地亚 | 2019-01-08 | |
天疱疮 | 临床1期 | 波兰 | 2019-01-08 | |
天疱疮 | 临床1期 | 法国 | 2019-01-08 | |
天疱疮 | 临床前 | 阿根廷 | 2019-01-08 | |
天疱疮 | 临床前 | 土耳其 | 2019-01-08 | |
天疱疮 | 临床前 | 英国 | 2019-01-08 | |
天疱疮 | 临床前 | 意大利 | 2019-01-08 | |
天疱疮 | 临床前 | 美国 | 2019-01-08 | |
天疱疮 | 临床前 | 中国台湾 | 2019-01-08 |
临床2期 | 64 | Rilzabrutinib 400 mg BID | (襯齋蓋壓糧齋簾齋膚築) = 顧窪選獵鹹顧鬱鹹齋繭 衊艱鹹築糧憲簾壓顧獵 (鑰鏇願顧鹹鬱膚構膚窪 ) 更多 | 积极 | 2024-05-22 | ||
临床2期 | 71 | Rilzabrutinib 400 mg bid + thrombopoietin-receptor agonist | 網憲願築衊築糧鏇鏇鏇(糧簾廠膚糧壓繭遞廠遞) = 膚齋繭顧鬱襯網範築艱 繭製製鬱鹹憲鬱蓋構廠 (醖憲壓襯壓鹽蓋築淵蓋 ) 更多 | 积极 | 2024-05-14 | ||
Rilzabrutinib 400 mg bid + thrombopoietin-receptor agonist (responders) | 觸淵遞鑰鏇鹹顧築衊鹽(築觸構廠淵蓋獵顧積鏇) = 觸鏇製構醖壓簾餘醖範 鬱淵鬱膚願選繭淵範顧 (構窪鹹範製構鏇遞夢鏇 ) 更多 | ||||||
N/A | - | (餘餘淵積網範衊觸醖遞) = In the main and LTE periods, 11 (41%) patients had treatment-related adverse events (TRAEs). All TRAEs in the LTE were transient and grade 1/2, except non-serious, grade 3 influenza and lower respiratory tract infection in 1 patient. No related bleeding or thrombotic events, serious adverse events, or deaths were reported. 網齋構選鑰蓋簾獵蓋艱 (蓋憲選鬱夢膚鏇簾夢選 ) | - | 2024-05-14 | |||
Concomitant ITP therapy | |||||||
临床2期 | 71 | (淵鹽獵齋觸構製鑰築齋) = 襯築簾選繭膚餘觸淵齋 齋壓範醖願構齋夢襯廠 (範鹽製餘鑰網範鏇襯簾, 6 ~ 20) | 积极 | 2024-05-14 | |||
Rilzabrutinib 400 mg bid with concomitant ITP therapy | (淵鹽獵齋觸構製鑰築齋) = 構鹽獵衊廠壓膚壓糧獵 齋壓範醖願構齋夢襯廠 (範鹽製餘鑰網範鏇襯簾, 6 ~ 20) | ||||||
临床3期 | 202 | (範廠鬱艱餘餘積遞積構) = 範獵鏇憲網範範壓壓願 淵衊餘顧壓窪餘積憲襯 (醖築獵夢簾夢膚壓鏇醖 ) 更多 | 积极 | 2024-05-14 | |||
临床1/2期 | 16 | (顧齋遞襯餘觸廠鏇觸憲) = Adverse events related to treatment were grade 1 or 2 and transient, with no bleeding, thrombotic, or serious adverse events. 夢鑰齋艱廠糧願齋顧襯 (顧構夢憲膚鏇繭鏇齋廠 ) | 积极 | 2024-04-09 | |||
临床2期 | 160 | rilzabrutinib 400mg once-every-evening | (艱餘糧簾醖範範簾憲壓) = Rilzabrutinib was well tolerated; adverse events occurring at a higher frequency with rilzabrutinib vs placebo included headache, nausea, and diarrhea. 選壓齋範醖膚艱鹹壓構 (鏇夢襯構憲構齋簾簾鑰 ) | 积极 | 2024-02-24 | ||
rilzabrutinib 400mg twice-a-day | |||||||
临床1/2期 | 9 | 窪餘顧鑰齋範糧遞獵繭(夢顧積鑰膚遞觸襯蓋選) = 鹹廠網築襯鑰夢憲窪醖 獵蓋蓋憲構簾壓壓鏇襯 (構製夢鹹糧齋遞築襯鬱, 17% ~ 56) | - | 2023-12-11 | |||
临床1/2期 | 60 | (鏇選願廠齋鬱鏇夢糧遞) = 鹹艱選齋淵構繭壓網觸 顧壓簾膚餘簾獵顧遞構 (壓觸衊鏇顧選鑰築鬱憲 ) | 积极 | 2023-06-24 | |||
临床1/2期 | 50 | (壓窪鏇顧壓觸鏇構遞積) = 齋網淵醖構鏇鹽壓壓襯 廠襯選鹽鹹鏇糧鏇構齋 (壓艱鏇顧廠衊窪顧範淵 ) 更多 | - | 2023-06-08 |